Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

Chest. 2008 Jul;134(1):187-92. doi: 10.1378/chest.07-1988.


Objective: To determine whether linezolid is safe and well tolerated in the treatment of extensively drug-resistant tuberculosis (XDR-TB).

Materials and methods: The was conducted in a specialized tuberculosis ward for multidrug-resistant tuberculosis (MDR-TB) on the Chest Service of Bellevue Hospital Center, which is a 768-bed public hospital in New York City. Seven patients with confirmed MDR-TB or XDR-TB who were still culture positive despite appropriate directly observed therapy were treated with a regimen containing linezolid and at least one other active agent.

Results: The linezolid-containing regimen led to sustained negative conversion of sputum cultures and radiographic improvement in all patients. Long-term therapy (longest duration of therapy, 28 months) was well tolerated in most patients. Neutropenia developed in three patients, but was reversible, and peripheral neuropathy developed in two patients.

Conclusions: Linezolid remains a promising possible addition to our therapeutic armamentarium against XDR-TB. Linezolid is associated with side effects that can be adequately managed. Further studies to define the mechanism of action and optimum dose should be performed.

Publication types

  • Case Reports

MeSH terms

  • Acetamides / adverse effects
  • Acetamides / therapeutic use*
  • Adult
  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / therapeutic use*
  • Child
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Extensively Drug-Resistant Tuberculosis / drug therapy
  • Female
  • Humans
  • Linezolid
  • Male
  • Middle Aged
  • Oxazolidinones / adverse effects
  • Oxazolidinones / therapeutic use*
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy*


  • Acetamides
  • Anti-Infective Agents
  • Oxazolidinones
  • Linezolid